Capricor Therapeutics Inc
CAPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$222.96M
Close$
$5.81
39.3% upside
Current Fair Value
39.3% upsideUndervalued by 39.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $222.96 Million |
|---|---|
| Enterprise Value | $150.66 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.26 |
| Beta | 0.42 |
| Outstanding Shares | 57,434,267 |
Return
| Return on Equity | -41.12% |
|---|---|
| Return on Assets | -35.12% |
| Return on Invested Capital | -39.78% |
Valuation & Multiples
| P/E Ratio | -1.66 |
|---|---|
| PEG | -4.24 |
| Price to Sales | - |
| Price to Book Ratio | 1.04 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.29 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$40.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$2.08 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4444▼ 37.35% |
|---|---|
| Total Calls | 3,385,731▼ 9.37% |
| Total Puts | 1,504,578▼ 50.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 58.90%▲ 2.76% |
|---|---|
| Total Invested | $1.03B▲ 29.94% |
| Investors Holding | 195▲ 45.00% |
ESG Score
No data
About Capricor Therapeutics Inc
CEO: Linda Marban